Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Odds of seronegativity were lower for participants who were SARS-CoV-2 seropositive pre-vaccination (aOR 0.2, 0.0 to 0.6) and for those taking vitamin D supplements (aOR 0.7, 0.5 to 0.9).
Source: Abstract. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Participants were invited via a national media campaign to complete an online baseline questionnaire to capture information on potential symptoms of COVID-19 experienced since 1 February 2020; results of any COVID-19 tests; and details of a wide range of potential risk factors for COVID-19 and determinants of vaccine response ().
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Determinants of Antibody Responses to SARS-CoV-2 Vaccines: Population-Based Longitudinal Study (COVIDENCE UK)
Study design awaiting verification · Vaccines · 2022
Original publication title
Determinants of Antibody Responses to SARS-CoV-2 Vaccines: Population-Based Longitudinal Study (COVIDENCE UK)
© 2022 by the authors.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Antibody responses to SARS-CoV-2 vaccines vary for reasons that remain poorly understood. A range of sociodemographic, behavioural, clinical, pharmacologic and nutritional factors could explain these differences. To investigate this hypothesis, we tested for presence of combined IgG, IgA and IgM (IgGAM) anti-Spike antibodies before and after 2 doses of ChAdOx1 nCoV-19 (ChAdOx1, AstraZeneca) or BNT162b2 (Pfizer-BioNTech) in UK adults participating in a population-based longitudinal study who received their first dose of vaccine between December 2020 and July 2021. Information on sixty-six potential sociodemographic, behavioural, clinical, pharmacologic and nutritional determinants of serological response to vaccination was captured using serial online questionnaires.
We used logistic regression to estimate multivariable-adjusted odds ratios (aORs) for associations between independent variables and risk of seronegativity following two vaccine doses. Additionally, percentage differences in antibody titres between groups were estimated in the sub-set of participants who were seropositive post-vaccination using linear regression. Anti-spike antibodies were undetectable in 378/9101 (4.2%) participants at a median of 8.6 weeks post second vaccine dose. Increased risk of post-vaccination seronegativity associated with administration of ChAdOx1 vs. BNT162b2 (adjusted odds ratio (aOR) 6.6, 95% CI 4.2 to 10.4), shorter interval between vaccine doses (aOR 1.6, 1.2 to 2.1, 6 to 10 vs. >10 weeks), poor vs. excellent general health (aOR 3.1, 1.4 to 7.0), immunodeficiency (aOR 6.5, 2.5 to 16.6) and immunosuppressant use (aOR 3.7, 2.4 to 5.7).
Odds of seronegativity were lower for participants who were SARS-CoV-2 seropositive pre-vaccination (aOR 0.2, 0.0 to 0.6) and for those taking vitamin D supplements (aOR 0.7, 0.5 to 0.9). Serologic responses to vaccination did not associate with time of day of vaccine administration, lifestyle factors including tobacco smoking, alcohol intake and sleep, or use of anti-pyretics for management of reactive symptoms after vaccination. In a sub-set of 8727 individuals who were seropositive post-vaccination, lower antibody titres associated with administration of ChAdOx1 vs. BNT162b2 (43.4% lower, 41.8 to 44.8), longer duration between second vaccine dose and sampling (12.7% lower, 8.2 to 16.9, for 9 to 16 weeks vs. 2 to 4 weeks), shorter interval between vaccine doses (10.4% lower, 3.7 to 16.7, for <6 weeks vs. >10 weeks), receiving a second vaccine dose in October: December vs. April: June (47.7% lower, 11.4 to 69.1), older age (3.3% lower per 10-year increase in age, 2.1 to 4.6), and hypertension (4.1% lower, 1.1 to 6.9).
Higher antibody titres associated with South Asian ethnicity (16.2% higher, 3.0 to 31.1, vs. White ethnicity) or Mixed/Multiple/Other ethnicity (11.8% higher, 2.9 to 21.6, vs. White ethnicity), higher body mass index (BMI; 2.9% higher, 0.2 to 5.7, for BMI 25 to 30 vs. <25 kg/m2) and pre-vaccination seropositivity for SARS-CoV-2 (105.1% higher, 94.1 to 116.6, for those seropositive and experienced COVID-19 symptoms vs. those who were seronegative pre-vaccination). In conclusion, we identify multiple determinants of antibody responses to SARS-CoV-2 vaccines, many of which are modifiable.
Authors’ abstract
Antibody responses to SARS-CoV-2 vaccines vary for reasons that remain poorly understood. A range of sociodemographic, behavioural, clinical, pharmacologic and nutritional factors could explain these differences. To investigate this hypothesis, we tested for presence of combined IgG, IgA and IgM (IgGAM) anti-Spike antibodies before and after 2 doses of ChAdOx1 nCoV-19 (ChAdOx1, AstraZeneca) or BNT162b2 (Pfizer-BioNTech) in UK adults participating in a population-based longitudinal study who received their first dose of vaccine between December 2020 and July 2021. Information on sixty-six potential sociodemographic, behavioural, clinical, pharmacologic and nutritional determinants of serological response to vaccination was captured using serial online questionnaires.
We used logistic regression to estimate multivariable-adjusted odds ratios (aORs) for associations between independent variables and risk of seronegativity following two vaccine doses. Additionally, percentage differences in antibody titres between groups were estimated in the sub-set of participants who were seropositive post-vaccination using linear regression. Anti-spike antibodies were undetectable in 378/9101 (4.2%) participants at a median of 8.6 weeks post second vaccine dose. Increased risk of post-vaccination seronegativity associated with administration of ChAdOx1 vs. BNT162b2 (adjusted odds ratio (aOR) 6.6, 95% CI 4.2 to 10.4), shorter interval between vaccine doses (aOR 1.6, 1.2 to 2.1, 6 to 10 vs. >10 weeks), poor vs. excellent general health (aOR 3.1, 1.4 to 7.0), immunodeficiency (aOR 6.5, 2.5 to 16.6) and immunosuppressant use (aOR 3.7, 2.4 to 5.7).
Odds of seronegativity were lower for participants who were SARS-CoV-2 seropositive pre-vaccination (aOR 0.2, 0.0 to 0.6) and for those taking vitamin D supplements (aOR 0.7, 0.5 to 0.9). Serologic responses to vaccination did not associate with time of day of vaccine administration, lifestyle factors including tobacco smoking, alcohol intake and sleep, or use of anti-pyretics for management of reactive symptoms after vaccination. In a sub-set of 8727 individuals who were seropositive post-vaccination, lower antibody titres associated with administration of ChAdOx1 vs. BNT162b2 (43.4% lower, 41.8 to 44.8), longer duration between second vaccine dose and sampling (12.7% lower, 8.2 to 16.9, for 9 to 16 weeks vs. 2 to 4 weeks), shorter interval between vaccine doses (10.4% lower, 3.7 to 16.7, for <6 weeks vs. >10 weeks), receiving a second vaccine dose in October: December vs. April: June (47.7% lower, 11.4 to 69.1), older age (3.3% lower per 10-year increase in age, 2.1 to 4.6), and hypertension (4.1% lower, 1.1 to 6.9).
Higher antibody titres associated with South Asian ethnicity (16.2% higher, 3.0 to 31.1, vs. White ethnicity) or Mixed/Multiple/Other ethnicity (11.8% higher, 2.9 to 21.6, vs. White ethnicity), higher body mass index (BMI; 2.9% higher, 0.2 to 5.7, for BMI 25 to 30 vs. <25 kg/m2) and pre-vaccination seropositivity for SARS-CoV-2 (105.1% higher, 94.1 to 116.6, for those seropositive and experienced COVID-19 symptoms vs. those who were seronegative pre-vaccination). In conclusion, we identify multiple determinants of antibody responses to SARS-CoV-2 vaccines, many of which are modifiable.
Publication and source details
Original title: Determinants of Antibody Responses to SARS-CoV-2 Vaccines: Population-Based Longitudinal Study (COVIDENCE UK)
David A. Jolliffe; Sian E. Faustini; Hayley Holt; Natalia Perdek; Sheena Maltby; Mohammad Talaei; Matthew Greenig; Giulia Vivaldi; Florence Tydeman; Jane Symons; Gwyneth A. Davies; Ronan A. Lyons; Christopher J. Griffiths; Frank Kee; Aziz Sheikh; Seif O. Shaheen; Alex G. Richter; Adrian R. Martineau
Vaccines · 2022
* Correspondence: a.martineau@qmul.ac.uk; Tel.: +44-207-882-7242© 2022 by the authors.2022https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).Barts CharityMGU0466MGU0459MGU0570Rosetrees Trust and The Bloom FoundationM771The Fischer Family TrustThe Exilarch’s FoundationUK National Institute for Health and Care Research Clinical Research Network 5225552257UK Research and Innovation Industrial Strategy Challenge FundMC_PC_19004This work was supported by Barts Charity (refs MGU0466, MGU0459 and MGU0570), Rosetrees Trust and The Bloom Foundation (ref M771), The Fischer Family Trust, The Exilarch’s Foundation, UK National Institute for Health and Care Research Clinical Research Network (refs 52255 and 52257), and the UK Research and Innovation Industrial Strategy Challenge Fund (ref MC_PC_19004).Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T08:57:17.022295+00:00
DOI: 10.3390/vaccines10101601 · PMC9610049